A Phase 1 interventional study of Rosuvastatin and Metformin HCl in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to investigate the relative bioavailability of rosuvastatin when given alone (Reference treatment, R) compared to when given together with one of the three different doses of metformin (10 mg, Test treatment 1 (T1); 50 mg (T2); 500 mg (T3)) or one of the two doses of furosemide (1 mg (T4); 5 mg (T5)).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1film-coated tablet as single dose, fasted
Drug: Rosuvastatin
Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
Drug: Rosuvastatin · Drug: Metformin HCl
Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
Drug: Rosuvastatin · Drug: Metformin HCl
Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
Drug: Rosuvastatin · Drug: Metformin HCl
Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
Drug: Rosuvastatin · Drug: Furosemide
Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
Drug: Rosuvastatin · Drug: Furosemide
Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)
This outcome measure presents the area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).
Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
Maximum Concentration of Rosuvastatin (Cmax)
This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax).
Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)
This outcome measure presents area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
All subjects were screened for eligibility to participate in the study. No run-in or wash-out period was conducted, since the trial was conducted in healthy subjects, that were not expected to take medications regularly. Actual number of subjects enrolled in fact represents randomized subjects due to the study set up.
| Milestone | Treatment (T) 1-T3-Reference (REF)-T5-T2-T4 | T2-REF-T4-T1-T5-T3 | T3-T5-T1-T4-REF-T2 | T4-T2-T5-REF-T3-T1 | T5-T4-T3-T2-T1-REF | REF-T1-T2-T3-T4-T5 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 |
| Received t1 | 3 | 2 | 3 | 3 | 2 | 2 |
| Received t2 | 3 | 3 | 3 | 3 | 2 | 3 |
| Received t3 | 2 | 2 | 3 | 3 | 2 | 3 |
| Received t4 | 3 | 2 | 3 | 3 | 2 | 2 |
| Received t5 | 3 | 2 | 3 | 3 | 3 | 2 |
| Received r | 3 | 2 | 3 | 3 | 2 | 3 |
| Completed | 3 | 2 | 3 | 3 | 2 | 2 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Consent withdrawn further participation | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 1 |
This outcome measure presents the area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).
| nanomol (nmol) * hour (h) / Litre (L) | REF Alone | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 |
|---|---|---|---|---|---|---|
| Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz) | 81.5 ± 50.9 | 87.8 ± 54.5 | 88.7 ± 62.4 | 126 ± 66.7 | 91.5 ± 55.4 | 97.2 ± 52.7 |
This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax).
| nmol/L | REF Alone | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 |
|---|---|---|---|---|---|---|
| Maximum Concentration of Rosuvastatin (Cmax) | 9.04 ± 52.4 | 9.59 ± 60.5 | 9.94 ± 69.4 | 14.0 ± 71.2 | 9.90 ± 62.0 | 10.8 ± 62.7 |
This outcome measure presents area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
| nmol*h/L | REF Alone | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 |
|---|---|---|---|---|---|---|
| Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞) | 99.7 ± 39.0 | 105 ± 48.0 | 102 ± 55.0 | 149 ± 49.8 | 108 ± 47.9 | 115 ± 42.0 |
Collected over From the first administration of study medication to the end of the 4 day residual effect period (96 hours after each administration of study medication) up to 24 days in total.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REF Alone | — | 0/16 (0%) | 4/16 (25%) |
| Treatment 1 | — | 0/15 (0%) | 4/15 (26.7%) |
| Treatment 2 | — | 0/17 (0%) | 2/17 (11.8%) |
| Treatment 3 | — | 0/15 (0%) | 2/15 (13.3%) |
| Treatment 4 | — | 0/15 (0%) | 3/15 (20%) |
| Treatment 5 | — | 0/16 (0%) | 2/16 (12.5%) |
| Event | REF Alone | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 | Treatment 5 |
|---|---|---|---|---|---|---|
| ToothacheGastrointestinal disorders | 1/16 | 0/15 | 0/17 | 0/15 | 1/15 | 0/16 |
| NasopharyngitisInfections and infestations | 0/16 | 0/15 | 0/17 | 1/15 | 0/15 | 1/16 |
| RhinitisInfections and infestations | 0/16 | 1/15 | 0/17 | 0/15 | 1/15 | 1/16 |
| ContusionInjury, poisoning and procedural complications | 0/16 | 1/15 | 0/17 | 0/15 | 0/15 | 0/16 |
| Procedural painInjury, poisoning and procedural complications | 0/16 | 0/15 | 0/17 | 0/15 | 1/15 | 0/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/16 | 1/15 | 0/17 | 0/15 | 0/15 | 0/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/16 | 1/15 | 0/17 | 0/15 | 0/15 | 0/16 |
| HeadacheNervous system disorders | 1/16 | 1/15 | 1/17 | 1/15 | 1/15 | 0/16 |
| ParaesthesiaNervous system disorders | 1/16 | 0/15 | 0/17 | 0/15 | 0/15 | 0/16 |
| HaematomaVascular disorders | 1/16 | 0/15 | 0/17 | 0/15 | 0/15 | 0/16 |
The randomised set (RS) includes all randomised subjects, whether treated or not.
| Age, Continuous(years) | Treatment (T) 1-T3-Reference (REF)-T5-T2-T4 | T2-REF-T4-T1-T5-T3 | T3-T5-T1-T4-REF-T2 | T4-T2-T5-REF-T3-T1 | T5-T4-T3-T2-T1-REF | REF-T1-T2-T3-T4-T5 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.0 ± 2.6 | 33.0 ± 8.7 | 39.3 ± 10.3 | 32.0 ± 14.1 | 22.0 ± 2.6 | 37.3 ± 12.9 | 31.9 ± 10.0 |
| Sex: Female, Male(Participants) | Treatment (T) 1-T3-Reference (REF)-T5-T2-T4 | T2-REF-T4-T1-T5-T3 | T3-T5-T1-T4-REF-T2 | T4-T2-T5-REF-T3-T1 | T5-T4-T3-T2-T1-REF | REF-T1-T2-T3-T4-T5 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 3 | 3 | 3 | 3 | 18 |
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Oct 2015 to primary completion in Dec 2015, 1 month.
Results were first posted in Feb 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Furosemide